All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021

Drugs

  • Drugs
    • Antibiotic
    • Antibody
    • Antibody-drug conjugate
    • Antigen
    • Antisense
    • Biosimilar
    • Bi-specific antibody
    • CAR T
    • Cell therapy
    • Chimeric antigen receptor technology
    • Enzyme
    • Gene therapy
    • Generic
    • Immuno-oncology
    • Microbiome
    • Monoclonal antibody
    • Nanotech
    • Natural
    • Oncolytic
    • Peptide
    • Plasma
    • Protein
    • RNAi
    • Small molecule
    • Vaccine
Home » Topics » Drugs
  • Gavel and medication
    Feb. 25, 2021
    By Mari Serebrov

    Biologic patent thickets, global settlements at stake in 7th Circuit case

    The U.S. Court of Appeals for the Seventh Circuit grappled with whether so-called patent thickets and certain global patent settlements constitute antitrust behavior as it heard arguments Feb. 25 in UFCW Local 1500 Welfare Fund v. Abbvie Inc.
  • Feb. 25, 2021
    By Michael Fitzhugh

    Sarepta wins accelerated FDA approval for third DMD therapy, casimersen

    As expected, the FDA granted an approval for Amondys 45 (casimersen), a new Duchenne muscular dystrophy (DMD) therapy developed by Sarepta Therapeutics Inc.
  • Jj covid 19 vaccine ad26cov2s 2 24
    Feb. 24, 2021
    By Randy Osborne

    One upmanship? J&J’s COVID-19 single-shot vaccine shortish on efficacy, long on other benefits

    Briefing documents released by the FDA related to the Vaccines and Related Products Advisory Committee meeting slated for Friday suggest that the COVID-19 vaccine from Johnson & Johnson (J&J) will sail smoothly to an emergency use authorization. “A century ago, [J&J] played a leading role in combatting the 1918 flu pandemic,” said Richard Nettles, the Whitehouse Station, N.J.-based company’s vice president of medical affairs in testimony Feb. 23 before the House Energy and Commerce Subcommittee on Oversight. “Our history of confronting global health care challenges continues to the present day, including with the European approval of our Ebola vaccine last year,” he added, saying the company “brought this same approach to the COVID-19 pandemic.”
Read More

Authors

  • Mark McCarty
  • Cormac Sheridan
  • Peter Winter
  • Lee Landenberger
  • Michael Fitzhugh
  • Marie Powers
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing